Correspondence: Hormone Therapy for Postmenopausal Women

TO THE EDITOR:

In an assessment of therapies to treat the symptoms of menopause, Pinkerton (Jan. 30 issue)[1] dismisses compounded therapies (except for those used in patients with allergies or when there is a medical need for unusual dosing regimens), and she notes safety concerns. This blanket generalization overlooks the substantial Food and Drug Administration (FDA) oversight established by the 2013 Drug Quality and Security Act (DQSA).

Contrary to Pinkerton's assertion of "minimal government regulation and monitoring," the drug outsourcing facilities supervised under the DQSA must register with the FDA, be subject to regular unannounced inspections, comply with Current Good Manufacturing Practices, and use FDA regulated ingredients. Patients have depended on compounders and outsourcing facilities for decades to provide the customized formulations that work well for them, along with counseling on use of the compounded medication. I am extremely concerned about the potential consequences for women who use these therapies of disregarding this sector in its entirety owing to unfounded safety concerns.

ERIKA SCHWARTZ, M.D.
EVOLVED SCIENCE
New York, NY
drerika@eshealt.com

No potential conflict of interest relevant to this letter was reported.

1. Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med 2020; 382: 446-55.

DOI: 10.1056/NEJMC2005199

TO THE EDITOR:

In her article on hormone therapy, Pinkerton focused on data from the Women's Health Initiative and did not mention the Danish Osteoporosis Prevention Study, which randomly assigned 1006 recently postmenopausal or perimenopausal women to estradiol or no estradiol for 11 years and followed them for 16 years. Women who received estradiol had significantly lower mortality (among 15 women vs. 26 women) and a significantly lower incidence of myocardial infarction (5 vs. 11) than women who did not receive estradiol, without an increase in the incidence of cancer (36 and 39, respectively), venous thromboembolism (2 and 1), or stroke (11 and 14).[1]

The article by Pinkerton also did not address sexual dysfunction[2] or menopause-related cognitive impairment,[3] which has been reported to be present in 60% of perimenopausal and postmenopausal women.[2-4] Subjective reports of symptoms are confirmed by objective evidence of decreases in measures of verbal memory, episodic memory, list learning, verbal fluency, or executive functioning.[2-4] Lack of awareness among physicians of this association between memory loss and menopause may have disastrous consequences for menopausal women, including the misdiagnosis of dementia in women with these symptoms.[3]

GAYATRI DEVI, M.D.
LENOX HILL HOSPITAL–NORTHWELL HEALTH
New York, NY
gd@ybrain.org

CHRIS CREATURA, M.D.
WEILL CORNELL MEDICINE
New York, NY

VIRGINIA R. DEVI-CHOU, M.A.
RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL
New Brunswick, NJ

No potential conflict of interest relevant to this letter was reported.

1. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345: e6409.

2. Davis SR, Lambrinoudaki I, Lumsden M, et al. Menopause. Nat Rev Dis Primers 2015; 1: 15004.

3. Devi G. Menopause-related cognitive impairment. Obstet Gynecol 2018; 132: 1325-7.

4. Greendale GA, Derby CA, Maki PM. Perimenopause and cognition. Obstet Gynecol Clin North Am 2011; 38: 519-35..

DOI: 10.1056/NEJMC2005199

THE AUTHOR REPLIES::

Schwartz notes concerns about the recommendation to avoid the use of compounded therapies except in special circumstances. The 2013 DQSA provides national licensure standards and FDA inspections for outsourcing wholesale distributors and third-party logistics providers who ship across state lines.[1] Compounding pharmacies that are not outsourcing providers are monitored by states, with wide variability in oversight.[1] The Pharmacy Compounding Accreditation Board assesses voluntary compliance with sterile and nonsterile pharmacy compounding processes. Major medical societies, including the American Medical Association, the American College of Obstetricians and Gynecologists, and the North American Menopause Society, recommend against compounded